Datopotamab mainly treats diseases

Datopotamab (Datopotamab) is an antibody-conjugated drug targeting Trop-2, which has received widespread attention in the field of tumor treatment in recent years. Trop-2 is a transmembrane glycoprotein highly expressed on the surface of various solid tumor cells and is closely related to tumor cell proliferation, invasion and metastasis. Dedabrotuzumab accurately recognizes Trop-2 through the antibody part and delivers the topoisomerase inhibitor-like cytotoxic load into tumor cells in a targeted manner, thereby achieving a more targeted killing effect. This is also an important reason why it has been focused on research and application in a variety of refractory tumors.

Currently, dabrotuzumab is mainly used to treat two major types of solid tumors. One is adult patients with unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer. Such patients have usually received endocrine therapy and chemotherapy, and subsequent treatment options are relatively limited. Studies believe that Trop-2 is commonly expressed in this type of breast cancer, giving dabrotomab a clear biological basis for late-line treatment. Targeted delivery of cytotoxic drugs can help to continue to control tumor progression after failure of previous treatments and improve the continuity of disease management.

The second one is an adult patient with locally advanced or metastatic non-small cell lung cancer with EGFR mutation who has received EGFR targeted therapy and platinum chemotherapy. For this group of patients, drug resistance is almost inevitable, and the treatment window is gradually narrowing. Dedabrotuzumab does not rely on the EGFR pathway to work, but attacks through a different target called Trop-2, so it has potential advantages across resistance mechanisms at both the theoretical and practical levels. Guidelines and research trends also show that Trop-2-targeted ADCs are gradually becoming an important exploration direction for late-line treatment of lung cancer.

Overall, the disease scope of dedabrotomab is concentrated in breast cancer and non-small cell lung cancer patients after multiple lines of treatment. Its core value is to provide new and precise medication pathways for patients with limited treatment options.

Reference materials:https://dailymed.nlm.nih.gov/